BiotechTube

Aliskiren + Valsartan

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Proteinuric Kidney Disease

Conditions

Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous

Trial Timeline

Sep 1, 2009 → Dec 1, 2012

NCT ID
NCT01129557

About Aliskiren + Valsartan

Aliskiren + Valsartan is a approved stage product being developed by Novartis for Proteinuric Kidney Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01129557. Target conditions include Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis.

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT01095822ApprovedUNKNOWN
NCT01129557ApprovedTerminated
NCT00416468Phase 1Completed
NCT00416728Phase 1Completed

Competing Products

4 competing products in Proteinuric Kidney Disease

See all competitors
ProductCompanyStageHype Score
InaxaplinVertex PharmaceuticalsPhase 2
42
VX-147 + PlaceboVertex PharmaceuticalsPhase 2/3
45
MZE829Maze TherapeuticsPhase 2
36
sparsentan + No sparsentanTravere TherapeuticsPhase 1
30